Agenus Q4 net loss $74M; botensilimab shows 23% ORR in MSS CRC, 50% in NSCLC

AGENUS INC

Q4 2022 revenue $28.4M, net loss $74.1M ($0.24/sh); FY22 revenue $98M, net loss $230.7M ($0.78/sh).
Cash & short-term investments $193M at Dec 31, 2022, down from $307M a year earlier.
Botensilimab/balstilimab combo: 23% ORR in MSS CRC (70 evaluable), 50% ORR in PD-(L)1 refractory NSCLC (8 evaluable).
Phase 3 confirmatory trial in MSS CRC expected in 2023; randomized Phase 2 ACTIVATE studies ongoing.
Potential future milestones from collaborations up to $2.7B; nine new partner trials launched in 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGENUS INC reported financial results for quarter and year ended December 31, 2022.

Period: quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 14, 2023, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001171843-23-001657

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.